Summary
Edwards Lifesciences Corporation (EW) filed an 8-K on July 29, 2021, to report its financial results for the second quarter of 2021. The key takeaway from this filing is the issuance of a press release containing the company's performance metrics for the period ending June 30, 2021. While the 8-K itself is a brief document primarily referencing the press release, investors should refer to the furnished Exhibit 99.1 for the detailed financial and operational data.
Key Highlights
- 1Edwards Lifesciences released its Q2 2021 financial results via an 8-K filing on July 29, 2021.
- 2The filing serves to formally incorporate the company's Q2 2021 earnings press release as an exhibit.
- 3Investors are directed to the press release (Exhibit 99.1) for specific financial performance details of the second quarter.
- 4The 8-K does not contain the detailed financial results itself but references the accompanying press release.
- 5The event date for reporting these results was July 28, 2021, with the filing occurring on July 29, 2021.
Frequently Asked Questions
The primary purpose of this 8-K filing is to officially report Edwards Lifesciences' financial results for the second quarter of 2021 by furnishing the related press release as an exhibit.
The detailed Q2 2021 financial results are located in the press release, dated July 29, 2021, which is furnished as Exhibit 99.1 to this 8-K filing.
This specific 8-K filing, as described in Item 2.02 and Item 9.01, is focused solely on reporting the Q2 2021 financial results. Any other operational updates would typically be found in separate 8-K filings or discussed in other company communications.